Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under...

Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Developmen

t for the Treatment of Hereditary Angioedema


"Data demonstrate the oral bioavailability of PHA121, which was well-tolerated across multiple ascending doses..."

012821 Pharvaris Announces Phase 1 Clini
.
Download • 54KB

Medical and Pharma Insider

A Program of FC Global Strategies LLC

383 Corona Street, Suite 589, Denver CO 80218 USA

Tel +1 303 478 4887

Website: www.medicalandpharmainsider.com

Email mail@medicalandpharmainsider.com

MedicalandPharmaInsider- (1).jpg
FC Global Strategies.png

©2021 Medical and Pharma Insider and FC Global Strategies LLC